Looking at Tigecycline, Pharma14’s proprietary Market Opportunity Locator indicates that this antbiotic drug has generic registration in various European countries including the USA and Canada.
Although Tigecycline has seen recent generic marketing launches, there still remain quite a few European countries where Pfizer's Tygacil is the only competitor on the market.
Countries' such as Cyprus, Denmark, Estonia, Iceland, Ireland, Latvia, Lithuania, Norway and Switzerland still have not seen any generic competition in Tigecycline.
Pharma14's "Market opportunity locator" is a live proprietary platform that tracks all registrations in 39 countries giving members of our platform direct insight when new generics are registered as well as when they appear on the market.
Sample data: Tigecycline. Competitive landscape.